-
Product Insights
Humoral Hypercalcemia of Malignancy - Drugs In Development, 2024
Empower your strategies with our Humoral Hypercalcemia of Malignancy – Drugs In Development, 2024 report and make more profitable business decisions. Humoral hypercalcemia of malignancy (HHM) is caused by too much parathyroid hormone-related peptide (PTHrP) from malignant tumors. Primary hyperparathyroidism, PTH production by malignant cells, local osteolytic hypercalcemia, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas can cause HHM. Symptoms include anxiety, depression, cognitive dysfunction, lethargy, weakness, fatigue, hyporeflexia, confusion, stupor, and in the most severe cases, coma. PTH and vitamin D levels,...
-
Product Insights
Mast Cell Leukemia - Drugs In Development, 2024
Empower your strategies with our Mast Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Mast cell leukemia (MCL) is a rare and aggressive type of blood cell cancer. It is a subtype of systemic mastocytosis (SM) and caused by the abnormal growth of cells from myeloid progenitor cells. Symptoms include lethargy and weakness, fainting, flushing, fever, tachycardia, losing more than 10 percent of body weight, diarrhea, nausea, and vomiting. MCL diagnosis requires fulfillment of diagnostic...
-
Product Insights
Vestibular Schwannoma (Acoustic Neuroma) - Drugs In Development, 2024
Empower your strategies with our Vestibular Schwannoma (Acoustic Neuroma) – Drugs In Development, 2024 report and make more profitable business decisions. Vestibular schwannoma is a benign, slow-growing tumor that develops from the balance and hearing nerves. It is also called an acoustic neuroma/neurinoma/neurilemma and is mainly caused by overproduction of Schwann cells. It affects the hearing and balance nerves, causing unilateral or asymmetric hearing loss, tinnitus, and dizziness/loss of balance. It can be diagnosed by thorough ear examination and hearing and...
-
Product Insights
Metastatic Bile Duct Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Bile Duct Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. The Metastatic Bile Duct Cancer drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
Bladder Carcinoma - Drugs In Development, 2024
Empower your strategies with our Bladder Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.Bladder cancer characteristically causes blood in the urine, which may be visible or detectable only by microscope. The best diagnosis of...
-
Product Insights
Myxoid Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Myxoid Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically. Myxoid/round cell liposarcoma, or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS usually grows in the arms and legs. These tumors grow slowly, and they can spread to other parts of the...
-
Product Insights
Retinoblastoma - Drugs In Development, 2024
Empower your strategies with our Retinoblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris, and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy, and surgery. The Retinoblastoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Malignant Fibrous Histiocytoma of Soft Tissue - Drugs In Development, 2024
Empower your strategies with our Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2024 report and make more profitable business decisions. Malignant fibrous histiocytoma (MFH), now known as undifferentiated pleomorphic sarcoma, is a type of cancerous tumor that originates in the bone or soft tissue or other organ parts of the body. It is the most common form of soft tissue tumors generally seen in adults and very rarely in children. It is a painless mass believed to originate...
-
Product Insights
Pheochromocytoma - Drugs In Development, 2024
Empower your strategies with our Pheochromocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1). The Pheochromocytoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Secondary CNS Lymphoma - Drugs In Development, 2024
Empower your strategies with our Secondary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoma in CNS (parts of the brain) is known as secondary CNS lymphoma (SCNSL). It is a form of CNS lymphoma where the risk of developing secondary lymphoma is 5-15%. It involves brain, eyes, spinal cord, meninges, as these are BBB (blood brain barriers) it creates a therapeutic challenge in managing this condition while relapse of the condition is also seen....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.